LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 230 participants.
Also called NCT05983250
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 230 participants
- Registry
-
NCT05983250
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- United States, Canada
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05983250. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-10 (actual); primary completion 2026-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
- Acronym
- LEVEL
- Condition
- Pulmonary Hypertension
- Intervention (Drug)
- TNX-103
- Intervention (Drug)
- Placebo
- Lead sponsor
- Tenax Therapeutics, Inc.
- Collaborator
- Medpace, Inc.
- Collaborator
- Northwestern University
Record details
- Record id
cardio:ct-nct05983250- Content hash
3f7592b9fe1eedba1827b87c4c3d7d9fcd6abfa0896135c68868d3523681d777